

# Is low dose aspirin associated with a reduced risk of overall cancer among the French population (ASPIK)

**First published:** 03/07/2018

**Last updated:** 23/04/2024

Study

Ongoing

## Administrative details

### PURI

<https://redirect.ema.europa.eu/resource/24723>

### EU PAS number

EUPAS24699

### Study ID

24723

### DARWIN EU® study

No

### Study countries

France

### Study status

Ongoing

## Research institution and networks

### Institutions

# Centre de pharmaco-épidémiologie de l'APHP

**First published:** 01/02/2024

Last updated 01/02/2024

Institution

## Contact details

### Study institution contact

Aya Ajrouche

Study contact

[aya.ajrouche@inserm.fr](mailto:aya.ajrouche@inserm.fr)

### Primary lead investigator

Aya Ajrouche

Primary lead investigator

## Study timelines

### Date when funding contract was signed

Planned:

03/02/2015

Actual:

03/02/2015

### Study start date

Planned:

02/01/2017

Actual:

02/01/2017

### Date of final study report

Planned:

01/10/2018

## Sources of funding

- Other

## More details on funding

Paris Diderot University, PHRC-k

## Regulatory

**Was the study required by a regulatory body?**

No

---

**Is the study required by a Risk Management Plan (RMP)?**

Not applicable

## Methodological aspects

### Study type

#### Study type list

**Study type:**

Non-interventional study

---

**Scope of the study:**

Effectiveness study (incl. comparative)

**Main study objective:**

This study aims to assess the effect of low dose aspirin use on overall cancer incidence among the French population.

## Study Design

**Non-interventional study design**

Cohort

## Study drug and medical condition

**Anatomical Therapeutic Chemical (ATC) code**

(B01AC06) acetylsalicylic acid

---

## Medical condition to be studied

Neoplasms malignant

## Population studied

### Age groups

Adults (46 to < 65 years)

Adults (65 to < 75 years)

Adults (75 to < 85 years)

Adults (85 years and over)

---

### Estimated number of subjects

111000

## Study design details

### Outcomes

overall cancer (excluding non melanoma skin cancer), specific cancer sites

---

### Data analysis plan

We estimated the effect of low dose aspirin on cancer incidence by using a dynamic model to account for the competing risk of death in the presence of time-dependent exposure and risk factors.

## Data management

## Data sources

### Data sources (types)

[Administrative data \(e.g. claims\)](#)

## Use of a Common Data Model (CDM)

### CDM mapping

No

## Data quality specifications

**Check conformance**

Unknown

---

**Check completeness**

Unknown

---

**Check stability**

Unknown

---

**Check logical consistency**

Unknown

**Data characterisation**

**Data characterisation conducted**

No